T
here is a well-established relationship between excess angiogenesis and progression of cancer and other pathological conditions, as well as impaired vascularization in ischemic conditions. This implies that anti-or proangiogenic treatments may be beneficial as a complement to existing therapies for a wide range of diseases. Development of efficient drugs that target the vasculature requires delineation of mechanisms that regulate blood vessel formation. The critical importance of growth factors and signal transduction by their cognate receptors, including vascular endothelial growth factors (VEGFs) and fibroblast growth factors (FGFs) in regulation of angiogenesis is widely recognized. 1, 2 However, we still need to identify their downstream molecular targets that regulate different aspects of the fine-tuned response resulting in formation of new vessels.
See accompanying article on page 2094
In the adult, new blood vessels form through distinct and overlapping mechanisms, depending on the microenvironment and the molecular context. [3] [4] [5] Sprouting angiogenesis is initiated when endothelial cells are stimulated by angiogenic growth factors eg, VEGF. The endothelial cells degrade the basement membrane of preexisting vessels, migrate into the surrounding matrix, proliferate, and finally differentiate to new, lumen containing vessels. Circulating endothelial cells or progenitors may contribute to a variable extent, forming new vessels through a process that largely resembles embryonic vasculogenesis. Finally, the newly formed vessel deposits a vascular basement membrane, and recruits stabilizing pericytes.
To define the proteome regulating endothelial differentiation to lumen-containing vessels, we used an in vitro model of tubular morphogenesis and screened for proteins that were tyrosine phosphorylated during this process. One of the identified phosphoproteins was ninein, a protein that has been shown to be involved in the minus-end anchoring of microtubules in the centrosome. 6 -8 In this study, we have analyzed expression of ninein in several types of endothelial cells in vitro and in vivo, and used advanced cell culture models to evaluate the role of ninein in blood vessel formation.
Methods

Cell Culture and In Vitro Angiogenesis Assays
Bovine capillary endothelial (BCE) cells from calf adrenal cortex were maintained in DMEM (Life Technologies), 10% newborn calf serum (NCS), and 2 ng/mL fibroblast growth factor-2 (FGF-2, Boehringer). Tubular morphogenesis was induced in a threedimensional (3D) collagen matrix in DMEM containing 10% NCS and 10 ng/mL FGF-2, as described. 9 Telomerase-immortalized human microvascular endothelial (TIME) cells 10 were cultured in EBM MV2 medium with supplements (5 ng/mL EGF, 0.2 g/mL hydrocortisone, 0.5 ng/mL VEGF-A, 10 ng/mL FGF-2, 20 ng/mL IGF-1; Promocell). Tube formation was induced in 3D collagen gels by 50 ng/mL VEGF-A (PeproTech) in EBM MV2 medium, 2% fetal bovine serum (FBS) as described. 11 Mouse ES cell line R1 12 was maintained on growth-arrested mouse embryonic fibroblasts in DMEM-Glutamax medium supplemented with 15% FBS, 25 mmol/L HEPES pH 7.4, 1.2 mmol/L sodium pyruvate, 0.12% monothiolglycerol and 1000 U/mL leukemia inhibitory factor. Embryoid bodies were induced as described 13 in the presence of VEGF-A (30 ng/mL, PeproTech), seeded in 8-well tissue-culture slides or in a 3D-collagen matrix to induce formation of endothelial sprouts and analyzed at day 8 or 12. 13 Porcine aortic endothelial (PAE) cells and human 293T cells were maintained in DMEM with 10%FBS, and human U2OS cells were maintained in RPMI with 10%FBS.
Cell Lysates and Western Blot Analysis
Cells were washed in PBS and lysed in boiling SDS sample buffer or in a modified RIPA buffer (1% Triton X-100, 40 mmol/L Tris-HCl, pH 8, 0.1% SDS) with complete protease inhibitor (Roche Applied Science). Extracts were fractionated on Novex NuPAGE (3% to 8% Tris-acetate) precast gels (Invitrogen). The membrane (Hybond-C extra, GE Healthcare) was blocked in 5% dry milk in 0.1% Tween, Tris-buffered saline (TTBS), and Western blot analysis was done as described. 9 Primary antibodies used were: antiphospho-tyrosine antibody 4G10 (Upstate Biotechnology), anti-␤-catenin (Transduction Laboratories), antininein produced in-house, 14 and antininein (Biolegend).
Purification and Identification of Phosphotyrosyl Proteins in Differentiating BCE Cells
Briefly, serum-starved BCE cells were cultured on collagen gels or gelatinized dishes and incubated in DMEM containing 10% NCS and 10 ng/mL FGF-2 for 24 hours at 37°C. Cells were lysed and phophotyrosine-containing proteines were immunoprecipitated using an antiphosphotyrosine (4G10)-agarose conjugate (Upstate Biotechnology). Proteins where separated by SDS-PAGE, the gel was silver stained, and protein bands where extracted by in-gel digestion. Identification of proteins was done using a Bruker Biflex III MALDI-TOF-MS (Bruker Daltonics). For a full description of methods involved, please see http://atvb.ahajournals.org.
Immunofluorescence
BCE cells, TIME cells, or embryoid bodies were washed in TBS, fixed for 30 minutes at rt or at 4°C overnight in zinc fix (0.1 mol/L Tris-HCl, pH 7.5, 3 mmol/L calcium acetate, 23 mmol/L zinc acetate, 37 mmol/L zinc chloride) containing 0.2% Triton X-100, blocked in 3% BSA in TBS for 1 hour at rt, and incubated with primary antibodies in blocking solution for 2 hours at rt. Samples were washed in TBS and incubated with Alexa-conjugated secondary antibodies (Molecular Probes) and/or phalloidin-Texas Red (Molecular Probes) in blocking solution for 1 hour at rt, followed by Hoechst 33342 nuclear staining.
Fully anonymized tissue samples were used in accordance with the Swedish biobank legislation. 14 anti-␤-tubulin (Molecular Probes), anti-␥-tubulin (Sigma), anti-CD31 (BD Biosciences) and antinerve glia 2 (NG2) (Chemicon).
Ninein-GFP cDNA Transfection
PAE and 293T cells were transfected with vectors encoding green fluorescent protein (GFP; pMaxGFP, Amaxa, Cologne, Germany) or ninein fused to GFP (ninein-GFP, 15 a kind gift from Dr Michel Bornens, Institute Curie, Paris, France) using Lipofectamine (Invitrogen) according to the manufacturer's instructions.
In Situ Proximity Ligation TIME cells were plated on gelatinized 8-well culture slides and cultured in EBM MV2 medium with supplements for 48 hours and fixed in in 2% paraformaldehyde, 15 minutes on ice. Tyrosine phosphorylated ninein was detected by the Proximity Ligation Assay (OLINK), through oligonucleotide-conjugated secondary antibodies. Close proximity of the secondary antibodies allows a rolling-circle amplification, detected by use of Texas Red-labeled probe (see www.olink.com). Primary antibodies used were rabbit-antininein (Abcam), combined with either mouse monoclonal antiphosphotyrosine 4G10 (Upstate Biotechnology) or mouse monoclonal antiphosphotyrosine p-Tyr-100 (Cell Signaling). As a negative control, a rabbit-anti-HA (human influenza hemagglutinin) antibody (Santa Cruz Biotechnology) was used in combination with a mouse antininein antibody. 14 Ninein siRNA Transfection TIME cells were seeded in 6-well tissue culture dishes 24 hours before transfection with siRNA targeting ninein (Nin-1, Nin-2) or control siRNA (Medium GC-content Stealth RNAi Negative control, Invitrogen) using Lipofectamine RNAiMAX Reagent (Invitrogen). At 48 hours posttransfection, cells were seeded on collagen matrices in 12-well plates for tube formation as described above. After 24 hours, tubular structures were fixed using zinc-fix containing 0.2% Triton X-100 and incubated with Texas Red-phalloidin (Molecular Probes) and Hoechst 33342. Samples were examined using a Nikon Eclipse E1000 microscope (Nikon). Images from 10ϫ or 4ϫ optical fields spanning the tube-forming area of each well were analyzed using Easy Image Analysis 2000 software (Rainfall). Total area of tubular structures were calculated, and the values of Nin-1 and Nin-2 treated cells were compared to nonsilencing control siRNA-treated cells.
Ninein targeting Stealth RNAi Duplexes (Invitrogen) used were: Nin-1: Sense: ACAAGAAGACAUUACUAACCCUGGC Antisense: GCCAGGGUUAGUAAUGUCUUCUUGU Nin-2: Sense: UUUAACUUCAGAGAGCUCCGCCUCC Antisense: GGAGGCGGAGCUCUCUGAAGUUAAA Immunohistochemical and immunofluorescence microscopy Samples were mounted using Fluoromount-G (Southern Biotech) and analyzed using a Nikon Eclipse E100 microscope (Nikon; Figure  4A ), a Nikon TE300 Eclipse inverted fluorescence microscope (Nikon; Figure 1A 
Statistical Examination
Statistical examination was performed on all data using ANOVA or unpaired Student t test using the Statview software. We considered a probability value less than 0.05 to be significant.
Results
To identify proteins that participate in formation of the vascular tube during angiogenesis, we used primary bovine capillary endothelial cells (BCE) that form vessel-like structures when cultured in a 3D-collagen matrix in the presence of FGF-2 ( Figure 1A) . Tyrosine phosphorylation is a hallmark of growth factor action. Western blot analysis of whole-cell lysates collected at different times visualized several proteins that were tyrosine phosphorylated during tubular morphogenesis ( Figure 1B ). In particular, we found a striking regulation of a prominent component of about 250 kDa (arrow). To allow further molecular characterization, tyrosine phosphorylated proteins retrieved from FGF-2-treated endothelial cells undergoing tubular morphogenesis were affinity purified using an antiphosphotyrosine-antibody column. Eluted proteins were separated by SDS-acrylamide gel electrophoresis. Silverstaining of the gel showed components with a relative migration rate of about 250 kDa, specifically induced in the FGF-2-treated condition. This region of the gel was cut out, subjected to in-gel trypsindigestion and mass spectrometry. Using this strategy, we identified 3 proteins whose molecular mass is compatible with a relative migration rate of about 250 kDa: filamin, nonmuscle myosin, and ninein.
We compared expression and activation of these proteins in extracts from BCE cells forming tubular structures in a 3D-collagen matrix or proliferating on gelatin. Immunoprecipitation with antiphosphotyrosine antibodies confirmed that ninein and nonmuscle myosin were tyrosine phosphorylated during tubular morphogenesis, with a maximal level of phosphorylation at 12 hours ( Figure 1C and data not shown). There was a slight phosphorylation of ninein also in the proliferating cells. The level of ninein expression increased during tubular morphogenesis as compared to proliferating cells (compare with ␤-catenin loading control; Figure 1C ). Tyrosine phosphorylation of ninein was also detected when examining telomerase-immortalized human microvascular endothelial (TIME) cells forming tubular structures in a 3D-collagen matrix in response to VEGF (data not shown). Importantly, ninein was not tyrosine phosphorylated in human fibroblast 293T cells or in human osteosarcoma U2OS cells ( Figure 1C ). We could not confirm tyrosine phosphorylation of filamin (data not shown), suggesting that filamin may be indirectly retained on the affinity-column through interaction with another phosphorylated protein.
The potential role of ninein during angiogenesis has not previously been investigated. Ninein was initially identified as a centrosome-marker, important for minus-end anchoring of microtubuli. 6, 8, 16 Whereas immunofluorescence analysis showed ninein colocalized with the centrosomal marker ␥-tubulin in nonendothelial cells, including U2OS and 293T, ninein was found both in the centrosome and throughout the Figure 2B , right panels). As expected, transfection of a vector expressing GFP alone resulted in cytoplasmic localization of GFP in both cell types (pMaxGFP; Figure 2B , left panels). The cytoplasmic distribution of ninein differed depending on the endothelial cell program. Thus, during FGF-2-induced proliferation of BCE cells cultured on gelatin, ninein was partially colocalized with the microtubular cytoskeleton ( Figure 2C and 2D, top panels) . This is in accordance with a previous report that demonstrated ninein traveling along microtubules to noncentrosomal sites during epithelial differentiation. 17 However, when BCE cells formed tubular structures in a collagen matrix, microtubular structures where less elaborate and both ninein and tubulin were found distributed throughout the cytoplasm ( Figure 2C and 2D, bottom panels). Cytoplasmic localization of ninein was consistently found throughout the tubular structures (supplemental Figure IB , please see http://atvb.ahajournals.org).
To determine the subcellular localization of tyrosine phosphorylated ninein in endothelial cells, we used the proximity ligation methodology, using oligonucleotide-conjugated secondary antibodies which when in close proximity allow an in situ PCR reaction. This is a sensitive method eg, for detection of protein modifications such as phosphorylation. Combining ninein primary antibodies with either of two different phospho-tyrosine antibodies (4G10 or p-Tyr-100) resulted in the detection of Texas Red-labeled RCA products (indicative of phosphorylated ninein) in the cytoplasm of TIME cells (supplemental Figure IIA) . VEGF-A induced an additional 2-fold increase in phosphorylated ninein in endothelial cells (supplemental Figure IIB and IIC) .
To further investigate whether ninein is expressed in endothelial cells in vivo, we performed immunofluorescence staining of frozen sections from human kidney, kidney tumor, and inflammatory tumor stroma. Vessels were visualized by staining with FITC-conjugated UEA-1. We found a high cytoplasmic expression of ninein in endothelial cells in a subset of vessels in normal kidney ( Figure 3A , arrowheads) and in pericytes/smooth muscle cells surrounding small arteries ( Figure 3A, arrows) . Similarly, kidney tumor vessels frequently expressed high levels of ninein in the cytoplasm ( Figure 3B, arrowheads) , whereas the surrounding tumor cells showed centrosomal localization of ninein. In the tumor stroma, endothelial cells in many vessels expressed high levels of ninein in the cytoplasm (Figure 3C, arrowheads) . Notably, ninein was localized in the centrosome in the majority of normal vessels, whereas a varying proportion of tumor vessels and stromal vessels showed centrosomal localization of ninein (see asterisk in Figure 3A, 3B, and 3D ). Nonendothelial cells in tumor and tumor stroma typically displayed a centrosomal localization of ninein ( Figure 3C , arrows). The centrosomal localization of ninein was verified through costaining with ␥-tubulin ( Figure 3D) .
The cytoplasmic localization of ninein in many tumor vessels prompted further analyses on whether ninein was expressed in the cytoplasm of endothelial cells during vascular development. VEGF-induced vascularization of embryoid bodies, aggregates of differentiating mouse embryonic stem cells, largely mimics vasculogenesis and angiogenesis in the mouse embryo. 18 Immunostaining of embryoid bodies revealed a high cytoplasmic expression of ninein in CD31-positive blood vessels ( Figure 4A ). To further explore ninein- expression during sprouting angiogenesis, we seeded embryoid bodies in a 3D collagen matrix and treated with VEGF for 12 days. In this model, endothelial cells migrate into the surrounding gel and form lumen-containing vessel structures that are guided by a nonproliferating tip-cell (overview of CD31-positive sprouts shown in Figure 4B) . A clear centrosomal localization of ninein was seen in the base of the endothelial sprout, although ninein was also distributed in the cytoplasm ( Figure 4C ). In the stalk, ninein was found in the centrosomes and cytoplasm of endothelial cells, as well as in NG2-positive pericytes ( Figure 4D ). This is in accordance with the cytoplasmic localization of ninein we detected in smooth muscle cells surrounding arteries eg, in the kidney ( Figure 3A) . Centrosomal localization of ninein was confirmed by costaining with ␥-tubulin in the stalk ( Figure 4E) . Interestingly, the most prominent cytoplasmic localization of ninein was found in the angiogenic tip-cell ( Figure 4F , overview of sprout shown in 4G). Filopodia extending from the tip-cell showed exceptionally strong ninein expression ( Figure 4F , arrows), compatible with a role for ninein in endothelial cell path-finding. Interestingly, we found both actin and ␣-tubulin expression in filopodia of tip-cells, suggesting that microtubules are involved in this process (supplemental Figure III) .
To determine whether ninein expression is required for endothelial differentiation to create vessel structures, ninein expression was silenced by siRNA targeting in TIME cells before VEGF-induced tubular morphogenesis. Ninein expression was efficiently attenuated by 2 different siRNAs, Nin1 and Nin2, as determined by RT-PCR ( Figure 5A ) and Western blot analysis ( Figure 5B ). Introduction of ninein siRNA led to decreased proliferation of endothelial cells, consistent with an important role of ninein in centrosomal function during mitosis ( Figure 5C ). Importantly, depletion of ninein in endothelial cells was associated with marked decrease in formation of tubular structures in response to VEGF ( Figure 5D , quantified in 5E). Ninein siRNA-transfected cells failed to arrange in long tubular structures, and instead, often formed nonorganized aggregates ( Figure 5D ). Similarly, decreased formation of vessel-like structures after ninein siRNA-transfection was observed for FGF-2-treated BCE cells (data not shown).
Discussion
Formation of the vascular tube requires dramatic changes in endothelial cell morphology, orchestrated by proteins that regulate the endothelial cytoskeleton. We found that the centrosomal protein ninein is expressed in the cytoplasm of endothelial cells during tubular morphogenesis in vitro and in the developing vasculature of embryoid bodies. Interestingly, depletion of ninein led to disruption of tubular morphogenesis. This was not attributable to inhibition of proliferation, as endothelial cells undergoing tubular morphogenesis are growth arrested. 19 Instead, ninein is likely to be involved in redistribution of the microtubule cytoskeleton important for migration and 3D organization of endothelial cells. In accordance, depletion of ninein is accompanied by disruption of the microtubule array, suggesting that ninein is required for maintaining cell shape. 20 Moreover, ninein overexpression interferes with recapture and release of microtubule minusends at the centrosome, with consequent inhibition of cell migration. 15 Immunostaining of human renal cancer and healthy control tissue demonstrated abundant expression of ninein in the cytoplasm of endothelial cells in a subset of vessels, whereas other endothelial cells showed a clear centrosomal location of ninein. Interestingly, although ninein was found in the centrosome in endothelial cells in the base of vascular sprouts in 3D embryoid body cultures, it was predominantly located in the cytoplasm of sprouting tip cells. Ninein has been shown to target ␥-tubulin to the centrosome, and overexpression of ninein leads to redistribution of ␥-tubulin to noncentrosomal sites. 21 Accordingly, we often found diffuse cytoplasmic expression of ␥-tubulin in endothelial cells with predominantly cytoplasmic ninein. We propose that cytoplasmic ninein is released from the centrosome during active angiogenesis, allowing minus-end anchoring of microtubules at noncentrosomal sites in endothelial cells (supplemental Figure IV) . Redistribution of microtubule nucleation proteins, including ninein, has previously been associated with differentiation of lens epithelium and muscle cells, 22, 23 and ninein resides in the cytoplasm in polarized cells such as developing neurons and epithelial cells. 6, 17, 24 Our data suggest that cytoplasmic ninein is instrumental in microtubule reorganization required for adaptation of endothelial cell morphology during angiogenesis. The extent of colocalization of ninein with ␥-tubulin or microtubules was not always prominent, however, and we cannot formally exclude other functions for ninein in endothelial cells.
Microtubule-targeted drugs (MTD)s are widely used in anticancer treatment and have antimitotic and antiangiogenic properties. 25 It has been shown that MTDs used as vascular disrupting agents specifically target tumor vasculature, suggesting a specific architecture of these vessels. Our results showing a cytoplasmic localization of ninein in many tumor vessels, may indeed reflect changes in patterning and/or stability of the microtubule network. Microtubule dynamics are modified by many different microtubule-interacting proteins, which are regulated by kinases and phosphatases downstream eg, growth factor signaling. Ninein interacts with GSK3␤, 26 and it has been shown that the coiled-coiled II domain can be phosphorylated by AuroraA and PKA. 27 In addition, ninein can be modified by SUMOylation, resulting in translocation from the centrosome to the nucleus. 28 We found that cytoplasmic ninein is tyrosine phosphorylated during tubular morphogenesis of endothelial cells. Of note, tyrosine phosphorylated ninein could not be detected in 293T or U2OS cells, where it has a clear centrosomal localization. There are 20 tyrosine residues in human ninein. According to the NetPhos phosphorylation site prediction bioinformatic tool (http://www.cbs.dtu.dk/services/NetPhos/), 29 10 of these are putative tyrosine phosphorylation sites. Future goals include to identify which tyrosine phosporylation site(s) in ninein that are regulated during angiogenesis and to further investigate the function of ninein tyrosine phosphorylation in endothelial cells. 
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